Drugs / sofentanil
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07505472 | Feb 2026 → Dec 2029 expected | rectal cancer | The First Hospital of Jilin University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sofentanil | “Patients in the experimental group of this study began continuous oral administration of sofentanil at a dose of 200 mg once daily, starting 2 days after completion of...” NCT07505472 ↗ |
| Route | Oral | “continuous oral administration of sofentanil” NCT07505472 ↗ |